IRCT20200420047147N1RecruitingPhase 2
Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 84
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •Patients who diagnosed with COVID-19 by RT-PCR test
- •Oxygen saturation less than 93%
- •Age more than 18 years old
- •To sign the informed consent form
Exclusion Criteria
- •Chronic kidney disease
- •Acute kidney injury
- •Chronic liver disease
- •pregnancy or breastfeeding
- •Pancreatitis
- •Allergy to Sitagliptin
- •Pemphigus disease history
Investigators
Similar Trials
Recruiting
Not Applicable
The evaluation of the efficacy of sitagliptin for NASH/NAFLD patients-a multicenter open-label studyJPRN-UMIN000005349Kyoto Prefectural University of Medicine, Department of Gastroenterology and Hepatology50
Completed
Not Applicable
Comparison of efficacy and safety of sitagliptin or ipragliflozin in type 2 diabetic patients with insulin therapyType 2 diabetesJPRN-UMIN000014139Yokohama City University70
Recruiting
Phase 3
Evaluation of the effectiveness of sitagliptin on metabolic factors and liver enzymesIRCT20191209045671N2Semnan University of Medical Sciences60
Not yet recruiting
Phase 4
A clinical study to understand the combined effects ofSitagliptin & metformin, in comparison to Glimepiride & metformin treatment in type 2 diabetes patientsCTRI/2024/04/065877Dr Keerthi Rajan M
Completed
Phase 2
Sitagliptin and Pioglitazon effects in the treatment of diabetesIRCT2015061619554N4Vice chancellor for research; Zanjan University of Medical Sciences160